Linperlisib

Generic Name: Linperlisib

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₃₇FN_₆O_₅S

CAS Number: 1702816-75-8

Unique Ingredient Identifier: 05HYK3CV9N

Indication: 用于既往接受过至少两种系统性治疗的复发或难治滤泡性淋巴瘤成人患者。

Clinical Trials

Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)

Phase 1

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: linperlisib and SHR2554

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 33

Registration Number: NCT06712173

Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)

Phase 1

Recruiting

Conditions: Lymphoma

Interventions: Drug: Linperlisib combination with obinutuzumab

First Posted Date: 2024-09-11

Last Posted Date: 2024-09-11

Lead Sponsor: The First Hospital of Jilin University

Target Recruit Count: 35

Registration Number: NCT06592170

Locations: 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China

A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma

Phase 2

Not yet recruiting

Conditions: Peripheral T Cell Lymphoma

Interventions: Drug: Linperlisib

First Posted Date: 2024-08-12

Last Posted Date: 2024-08-12

Lead Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Target Recruit Count: 606

Registration Number: NCT06548347

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Phase 2

Recruiting

Conditions: Relapsed/Refractory Large B-Cell Lymphoma

Interventions: Drug: Linperlisib
Drug: Rituximab
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Dexamethasone
Drug: Cisplatin
Drug: Ara-C
Drug: Vinorelbine
Drug: Mitoxantrone hydrochloride liposome

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 89

Registration Number: NCT06489808

Locations: 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China

Linperlisib Combined With Chidamide in Patients With PTCL

Phase 1

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Linperlisib and chidamide
Drug: cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone

First Posted Date: 2024-05-20

Last Posted Date: 2024-05-20

Lead Sponsor: Yanyan Liu

Target Recruit Count: 100

Registration Number: NCT06421948

Locations: 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

Phase 1

Recruiting

Conditions: T-lymphoblastic Lymphoma
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Interventions: Drug: Linperlisib
Drug: Camrelizumab
Drug: Pegaspargase
Drug: Dexamethasone

First Posted Date: 2024-04-19

Last Posted Date: 2024-04-19

Lead Sponsor: Beijing Tongren Hospital

Target Recruit Count: 43

Registration Number: NCT06376721

Locations: 🇨🇳
Liang Wang, Beijing, Beijing, China

Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)

Phase 2

Recruiting

Conditions: Nodal T-follicular Helper Cell Lymphoma

Interventions: Drug: linperlisib combined with CHOP regimen

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Peking University

Target Recruit Count: 54

Registration Number: NCT06347653

Locations: 🇨🇳
Bejing Cancer Hospital, Beijing, Beijing, China

A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma

Phase 4

Not yet recruiting

Conditions: Indolent B-cell Lymphoma

Interventions: Drug: Linperlisib

First Posted Date: 2024-04-03

Last Posted Date: 2024-04-03

Lead Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.

Target Recruit Count: 88

Registration Number: NCT06343935

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Phase 2

Not yet recruiting

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Linperlisib in combination with Obinutuzumab and Venetoclax

First Posted Date: 2024-03-22

Last Posted Date: 2024-03-22

Lead Sponsor: Dalian Medical University

Target Recruit Count: 10

Registration Number: NCT06324994

Locations: 🇨🇳
The Second Hospital Dalian Medical University, Dalian, Liaoning, China

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Phase 2

Recruiting

Conditions: Relapsed/Refractory Large Granular T Lymphocytic Leukemia

Interventions: Drug: Linperlisib

First Posted Date: 2024-01-25

Last Posted Date: 2024-01-25

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 41

Registration Number: NCT06224257

Locations: 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy